Erika Cyphert

Dr. Erika Cyphert

Cornell University, Ithaca, NY, USA 14853
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in Antibiotics
Verified
Journal Article
Open access
PDF file
ECErika Cyphert
Erika Cyphert
JWJaqueline D. Wallat
Jaqueline D. Wallat
JPJonathan Pokorski
Jonathan Pokorski
HRHorst Von Recum
Horst Von Recum
The antibiotic erythromycin has limited efficacy and bioavailability due to its instability and conversion under acidic conditions via an intramolecular dehydration reaction. To improve the stability of erythromycin, several analogs have been developed—such as azithromycin and clarithromycin—which decrease the rate of intramolecular dehydration. We set out to build upon this prior work by developing a conjugate of erythromycin with improved pH stability, bioavailability, and preferential release from a drug delivery system directly at the low pH of an infection site. To develop this new drug conjugate, adamantane-1-carbohydrazide was covalently attached to erythromycin via a pH-degradable hydrazone bond. Since Staphylococcus aureus infection sites are slightly acidic, the hydrazone bond will undergo hydrolysis liberating erythromycin directly at the infection site. The adamantane group provides interaction with the drug delivery system. This local delivery strategy has the potential of reducing off-target and systemic side-effects. This work demonstrates the synthesis of a pH-cleavable, erythromycin conjugate that retains the inherent antimicrobial activity of erythromycin, has an increased hydrophobicity, and improved stability in acidic conditions; thereby enhancing erythromycin’s bioavailability while simultaneously reducing its toxicity.

11 November 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
ECErika Cyphert
Erika Cyphert
NZNingjing Zhang
Ningjing Zhang
GLGreg D. Learn
Greg D. Learn
CHChristopher J. Hernandez
Christopher J. Hernandez
HRHorst Von Recum
Horst Von Recum

26 December 2019 in Biomacromolecules
Verified
Journal Article
Closed access
ECErika Cyphert
Erika Cyphert
CLChao-Yi Lu
Chao-Yi Lu
DMDylan W. Marques
Dylan W. Marques
GLGreg Learn
Greg Learn
HRHorst Von Recum
Horst Von Recum

11 June 2020 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
ECErika Cyphert
Erika Cyphert
GLGreg D. Learn
Greg D. Learn
DMDylan W. Marques
Dylan W. Marques
CLChao-Yi Lu
Chao-Yi Lu
HRHorst Von Recum
Horst Von Recum

8 February 2017 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
ECErika Cyphert
Erika Cyphert
AFAndrew S Fu
Andrew S Fu
HRHorst Von Recum
Horst Von Recum
Doxorubicin is a chemotherapeutic drug typically administered systemically which frequently leads to cardiac and hepatic toxicities. Local delivery to a tumor has a chance to mitigate some of these toxicities and can further be mitigated by including a means of tumor-specific drug release. Our laboratory has explored the use of molecular interactions to control the rate of drug release beyond that capable of diffusion alone. To this system, we added an additional affinity group (adamantane) to doxorubicin through a pH-sensitive hydrazone bond. The result was a modified doxorubicin which had an even higher affinity to our drug delivery polymer, and virtually no release in normal conditions, but showed accelerated release of drug in tumor-like low pH. Further, we show that adamantane-modified doxorubicin (adamantane-doxorubicin) and cleaved adamantane-doxorubicin showed equivalent capacity to kill human U-87 glioblastoma cells in vitro as unmodified doxorubicin. Taken together, these data demonstrate our ability to load high levels of modified chemotherapeutic drugs into our affinity-based delivery platform and deliver these drugs almost exclusively in the acidic microenvironments, such as those surrounding the tumor tissue via pH-cleavable bond while minimizing drug delivery in neutral pH tissue, with the ultimate goal of reducing systemic through better local delivery.Impact statement: Doxorubicin (DOX) is especially cytotoxic to the heart, liver, kidneys, and healthy tissues surrounding the tumor microenvironment. This systemic toxicity can be partially addressed by local, tumor-specific drug delivery systems. While pH-sensitive DOX delivery systems have been developed by several other groups, many lack a prolonged and consistent release profile required to successfully treat heterogeneous tumors. Our system of a chemically modified form of DOX combined with an affinity-based cyclodextrin delivery system is capable of delivering DOX for 87 days while maintaining its the drug cytotoxicity. This finding is particularly relevant to improving cancer treatments because it enables regulated local delivery of DOX specifically to tumor tissue and allows the drug to be continuously delivered over a therapeutically relevant amount of time.

3 February 2022 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
ECErika Cyphert
Erika Cyphert
NKNithya Kanagasegar
Nithya Kanagasegar
NZNingjing Zhang
Ningjing Zhang
GLGreg D. Learn
Greg D. Learn
HRHorst Von Recum
Horst Von Recum